{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-033724","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.934908+00:00","generated_at":"2026-05-15T09:10:57.025252+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocugen reports 31% reduction in GA lesion growth at 12 months in Phase 2 OCU410 trial; plans Phase 3 in Q3 2026","bullets":["31% reduction in GA lesion growth (medium dose) vs control at 12 months (p<0.05); 55% of treated patients had ≥30% lesion reduction.","No OCU410-related serious adverse events; no endophthalmitis, retinal detachment, or vasculitis reported.","27% slower rate of ellipsoid zone loss vs control, indicating photoreceptor preservation.","Phase 3 pivotal trial with up to 300 subjects, adaptive design >95% power, expected to start Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-033724","json":"https://secwatch.observer/filing/0001104659-26-033724.json","markdown":"https://secwatch.observer/filing/0001104659-26-033724.md","text":"https://secwatch.observer/filing/0001104659-26-033724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926033724/0001104659-26-033724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926033724/tm269664d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:10:57.025252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}